- Home
- JCE vs ARCT Comparison
JCE vs ARCT Comparison
Compare JCE & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCE
- ARCT
- Stock Information
- Founded
- JCE 2007
- ARCT 2013
- Country
- JCE United States
- ARCT United States
- Employees
- JCE N/A
- ARCT N/A
- Industry
- JCE Trusts Except Educational Religious and Charitable
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- JCE Finance
- ARCT Health Care
- Exchange
- JCE Nasdaq
- ARCT Nasdaq
- Market Cap
- JCE 253.3M
- ARCT 298.3M
- IPO Year
- JCE N/A
- ARCT N/A
- Fundamental
- Price
- JCE $15.46
- ARCT $13.10
- Analyst Decision
- JCE
- ARCT Strong Buy
- Analyst Count
- JCE 0
- ARCT 8
- Target Price
- JCE N/A
- ARCT $52.33
- AVG Volume (30 Days)
- JCE 49.7K
- ARCT 494.3K
- Earning Date
- JCE 01-01-0001
- ARCT 08-04-2025
- Dividend Yield
- JCE 9.26%
- ARCT N/A
- EPS Growth
- JCE N/A
- ARCT N/A
- EPS
- JCE N/A
- ARCT N/A
- Revenue
- JCE N/A
- ARCT $143,680,000.00
- Revenue This Year
- JCE N/A
- ARCT N/A
- Revenue Next Year
- JCE N/A
- ARCT $34.79
- P/E Ratio
- JCE N/A
- ARCT N/A
- Revenue Growth
- JCE N/A
- ARCT 15.38
- 52 Week Low
- JCE $11.64
- ARCT $8.04
- 52 Week High
- JCE $14.28
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- JCE 63.60
- ARCT 51.41
- Support Level
- JCE $14.36
- ARCT $12.03
- Resistance Level
- JCE $15.30
- ARCT $14.58
- Average True Range (ATR)
- JCE 0.26
- ARCT 0.91
- MACD
- JCE 0.03
- ARCT 0.03
- Stochastic Oscillator
- JCE 91.60
- ARCT 32.66
About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.